雾化吸入肝素防治支气管哮喘的临床研究  

Clinical Study of Heparin Spray Inhalation in Treatment of Bronchial Asthma

作　　者：刘小辉[1] 刘小民[1] 江玲[1] 

机构地区：[1]中国人民解放军第451医院神经内科,陕西省西安市710054

出　　处：《中国全科医学》2006年第11期925-926,共2页Chinese General Practice

摘　　要：目的探讨雾化吸入肝素防治支气管哮喘的疗效。方法采用随机单盲交叉分组的自身对照设计,对40例轻、中度哮喘患者吸入肝素前、后进行肺功能、痰液嗜酸粒细胞阳离子蛋白(ECP)、TNF-α、sIL-2R水平测定。并先后于吸入肝素及吸入安慰剂后进行气道反应性测定。结果吸入肝素前、后痰液ECP、TNF-α、sIL-2R水平间差异有显著性意义(P<0·05);吸入肝素前、后肺功能1s用力呼气容积(FEV1)、最大呼吸流速(PEFR)、用力肺活量(FVC)间差异有显著性意义(P<0·05)。所有患者吸入肝素后的PC20值均较吸入安慰剂高,PC20-Mch值间差异有显著性意义(P<0·05),其中4例吸入肝素后气道反应转为阳性。结论肝素有一定的支气管扩张作用,雾化吸入后可明显抑制气道炎性反应,起效快、疗效高,可早期防治哮喘。Objective To investigate the preventive and therapeutic effect of hepafin spray inhalation for bronchial asthma. Methods A randomized, single - blind and auto - controlled trial was designed for 40 patients with bronchial asthma at mild or middle degree ; before and after hepafin spray inhalation and placebo were given, pulmonary function and the level of sputum ECP, TNF-α and sIL-2 were measured and the airway response were examined. Results After the patients were given heparin spray inhalation, their levels of sputum ECP, TNF -α and sIL -2R were reduced （ P 〈0. 05） ; FEV1, PEFR and FVC increased （ P 〈0. 05）. The levels of PC20 in all patients treated by heparin were significantly higher than those by placebo. There a significant difference between the two groups in PC20 - Mch value （ P 〈 0. 05 ）. There were 4 cases whose airway response turned into positive after heparin treatment. Conclusion Hepafin spray inhalation can reduce the airway inflammatory response remarkably in asthmatics. It is of a certain action of dilating bronchi, being quickly responded and highly effective, may be used for prevention and treatment of bronchial asthma.

关 键 词：肝素 哮喘 雾化吸入 研究 

分 类 号：R562.25[医药卫生—呼吸系统]